Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (IVT PCV-25)
A Phase 1, Multicenter, Randomized, Active-Controlled, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Inventprise's 25-Valent Pneumococcal Conjugate Vaccine in Healthy PCV-Naïve Adults (18 Through 40 Years)
Sponsor: Canadian Center for Vaccinology
This PHASE1 trial investigates Pneumococcal Vaccines and is currently completed. Canadian Center for Vaccinology leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed · Phase: PHASE1_PHASE2 → PHASE1
-
Dec 2022 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Canadian Center for Vaccinology
- Inventprise Inc.
- PATH
- Vaccine Evaluation Center, Canada
For direct contact, visit the study record on ClinicalTrials.gov .